Integra LifeSciences Ownership
| IART Stock | USD 24.18 0.08 0.33% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 77 M | Current Value 76 M | Avarage Shares Outstanding 72.8 M | Quarterly Volatility 11.3 M |
Integra |
Integra Stock Ownership Analysis
About 14.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.23. Some equities with similar Price to Book (P/B) outperform the market in the long run. Integra LifeSciences has Price/Earnings To Growth (PEG) ratio of 0.81. The entity recorded a loss per share of 0.09. The firm had not issued any dividends in recent years. Integra LifeSciences had 2:1 split on the 4th of January 2017. Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. Integra Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 3800 people. To learn more about Integra LifeSciences Holdings call Jan Witte at 609 275 0500 or check out https://www.integralife.com.Besides selling stocks to institutional investors, Integra LifeSciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Integra LifeSciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Integra LifeSciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Integra LifeSciences Quarterly Liabilities And Stockholders Equity |
|
Integra LifeSciences Insider Trades History
About 14.0% of Integra LifeSciences Holdings are currently held by insiders. Unlike Integra LifeSciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Integra LifeSciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Integra LifeSciences' insider trades
Integra Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Integra LifeSciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Integra LifeSciences Holdings backward and forwards among themselves. Integra LifeSciences' institutional investor refers to the entity that pools money to purchase Integra LifeSciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.8 M | Goldman Sachs Group Inc | 2024-09-30 | 1.3 M | Capital Research Global Investors | 2024-09-30 | 1.3 M | Voloridge Investment Management, Llc | 2024-09-30 | 1.1 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1 M | D. E. Shaw & Co Lp | 2024-09-30 | 1 M | Neuberger Berman Group Llc | 2024-09-30 | 875.6 K | Northern Trust Corp | 2024-09-30 | 812.3 K | Bank Of America Corp | 2024-09-30 | 794.7 K | Blackrock Inc | 2024-09-30 | 10.9 M | Vanguard Group Inc | 2024-09-30 | 7.7 M |
Integra LifeSciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Integra LifeSciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Integra LifeSciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Integra LifeSciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Integra LifeSciences' latest congressional trading
Congressional trading in companies like Integra LifeSciences, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Integra LifeSciences by those in governmental positions are based on the same information available to the general public.
| 2024-07-09 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Integra LifeSciences Outstanding Bonds
Integra LifeSciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Integra LifeSciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Integra bonds can be classified according to their maturity, which is the date when Integra LifeSciences Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US457985AM13 Corp BondUS457985AM13 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Integra LifeSciences Corporate Filings
F4 | 8th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 7th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 6th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.